LENZ Therapeutics’ (LENZ) “Buy” Rating Reiterated at HC Wainwright

by · The Cerbat Gem

HC Wainwright reiterated their buy rating on shares of LENZ Therapeutics (NASDAQ:LENZ – Free Report) in a research note published on Thursday,Benzinga reports. The brokerage currently has a $38.00 price target on the stock.

Other equities analysts also recently issued reports about the company. Raymond James began coverage on LENZ Therapeutics in a report on Friday, September 27th. They issued an “outperform” rating and a $37.00 price objective for the company. Piper Sandler restated an “overweight” rating and set a $36.00 price target on shares of LENZ Therapeutics in a research note on Thursday, August 15th. Finally, William Blair raised shares of LENZ Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, LENZ Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $35.40.

Get Our Latest Analysis on LENZ Therapeutics

LENZ Therapeutics Trading Up 5.0 %

Shares of NASDAQ:LENZ traded up $1.62 during trading on Thursday, reaching $34.15. 104,805 shares of the stock traded hands, compared to its average volume of 136,035. The stock has a 50-day moving average of $24.70 and a two-hundred day moving average of $21.07. LENZ Therapeutics has a 52-week low of $14.07 and a 52-week high of $37.13.

LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.09. On average, equities research analysts forecast that LENZ Therapeutics will post -3.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GSA Capital Partners LLP purchased a new position in LENZ Therapeutics during the third quarter valued at $246,000. SG Americas Securities LLC bought a new position in shares of LENZ Therapeutics during the 3rd quarter valued at about $107,000. Deerfield Management Company L.P. Series C purchased a new stake in shares of LENZ Therapeutics in the second quarter worth about $300,000. Squarepoint Ops LLC purchased a new stake in shares of LENZ Therapeutics in the second quarter worth about $181,000. Finally, Marshall Wace LLP bought a new position in LENZ Therapeutics during the second quarter valued at approximately $390,000. 54.32% of the stock is currently owned by institutional investors.

About LENZ Therapeutics

(Get Free Report)

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Read More